In addition, existing tissue-based immunotherapy biomarkers such as PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI) have intrinsic limitations, including the invasiveness of sample collection, intra-tumor heterogeneity, and the lack of validation for clinical use in multiple tumor types [13,14,15]. This evidence concerns the gene CD274 and neoplasm.